{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:17:21Z","timestamp":1767651441555,"version":"3.40.5"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"crossref","award":["cstc2019jcyj-msxmX0117"],"award-info":[{"award-number":["cstc2019jcyj-msxmX0117"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chongqing Medical Scientific Research Project (Joint project of the Chongqing Health Commission and the Bureau of Science and Technology","award":["2022MSXM017"],"award-info":[{"award-number":["2022MSXM017"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,27]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Drug hypersensitivity syndrome (DIHS) is a rare but potentially fatal adverse drug reaction characterized by fever, rash, and visceral organ damage, particularly affecting the liver. Early recognition and appropriate management are crucial to prevent serious complications. However, there is limited information on the clinical presentation and management of DIHS, especially in the context of antiepileptic drugs. This case report aims to highlight the importance of recognizing subtle clinical signs and symptoms of DIHS, which can be easily overlooked, particularly in the context of antiepileptic drug use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a case of a 15-year-old male patient who developed DIHS after being prescribed phenytoin sodium for epilepsy. The patient presented with symptoms of fever, sore throat, rash, jaundice, and liver dysfunction. Initially, the patient did not receive glucocorticoids and experienced additional reactions to cefoxitin and phosphatidylcholine, likely due to cross-reactivity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The diagnosis of DIHS was made based on the patient\u2019s clinical presentation, including fever, extensive rash, organ involvement, and hematological abnormalities. The temporal association with the use of phenytoin sodium, along with the exclusion of other causes of fever and rash, supported the diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Upon initiation of glucocorticoid therapy with dexamethasone, the patient\u2019s symptoms significantly improved. The rash and pruritus decreased, and laboratory values showed improvement, with a decrease in liver enzymes and normalization of white blood cell counts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient\u2019s fever resolved within 48 hours of starting corticosteroids, and there was no evidence of ongoing inflammation as indicated by a decrease in C-reactive protein levels. Furthermore, the patient\u2019s 30-month follow-up revealed no recurrence of rash, liver dysfunction, or organic damage, indicating the long-term effectiveness of the treatment administered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case highlights the importance of recognizing the subtle clinical signs and symptoms of DIHS, especially in the context of antiepileptic drug use. It underscores the potential benefits of early initiation of glucocorticoid therapy in managing DIHS. The case also serves as a reminder of the potential for drug cross-reactivity in DIHS and the need for cautious drug selection during the acute phase of the syndrome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000039715","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T21:02:30Z","timestamp":1727470950000},"page":"e39715","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Drug-induced hypersensitivity syndrome due to phenytoin: Case report and review of the literature"],"prefix":"10.1097","volume":"103","author":[{"given":"Ling","family":"Wang","sequence":"first","affiliation":[{"name":"Chongqing Medical University, Yuzhong District, Chongqing, China"},{"name":"Department of Geriatric, Chongqing General Hospital, Chongqing University, Yuzhong District, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatric, Chongqing General Hospital, Chongqing University, Yuzhong District, Chongqing, China"},{"name":"Chongqing Clinical Research Centre for Geriatic Diseases."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xichun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatric, Chongqing General Hospital, Chongqing University, Yuzhong District, Chongqing, China"},{"name":"Chongqing Clinical Research Centre for Geriatic Diseases."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7772-3548","authenticated-orcid":false,"given":"Yali","family":"Xu","sequence":"additional","affiliation":[{"name":"Chongqing Medical University, Yuzhong District, Chongqing, China"},{"name":"Department of Geriatric, Chongqing General Hospital, Chongqing University, Yuzhong District, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1187937","DOI":"10.3389\/fmed.2023.1187937","article-title":"Advances in understanding of the pathogenesis and therapeutic implications of drug reactions with eosinophilia and systemic symptoms: an updated review.","volume":"10","author":"Chen","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019.","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.anai.2024.02.003","article-title":"The incidence of drug-induced hypersensitivity syndrome associated with levetiracetam and clobazam is likely underreported.","volume":"132","author":"Kichili","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"journal-title":"J Immunol Res","article-title":"Recent advances in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms.","author":"Watanabe","key":"R4-20250504"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/ced.12682","article-title":"Drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome: clinical features of 27 patients.","volume":"40","author":"Avancini","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1346-8138.2004.tb00645.x","article-title":"Drug-induced hypersensitivity syndrome due to anticonvulsants in a two-year-old boy.","volume":"31","author":"Criado","year":"2004","journal-title":"J Dermatol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/all.12602","article-title":"Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions\u2014a prospective comparative study.","volume":"70","author":"Chen","year":"2015","journal-title":"Allergy"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/1346-8138.16575","article-title":"Increased expression of human herpes virus 6 receptor CD134\/OX40 in skin lesions of patients with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms.","volume":"50","author":"Lee","year":"2023","journal-title":"J Dermatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40257-018-00416-4","article-title":"Drug reaction with eosinophilia and systemic symptoms (DReSS): how far have we come?","volume":"20","author":"Martinez-Cabriales","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/ijms22042147","article-title":"Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS).","volume":"22","author":"Miyagawa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1338247","DOI":"10.3389\/fmed.2024.1338247","article-title":"Drug-induced hypersensitivity syndrome related to piperacillin-tazobactam: a case report and review of the literature.","volume":"11","author":"Shen","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1140339","DOI":"10.3389\/fmed.2023.1140339","article-title":"Case report: sulfasalazine-induced hypersensitivity.","volume":"10","author":"Kuchinskaya","year":"2023","journal-title":"Front Med (Lausanne)"},{"journal-title":"J Am Acad Dermatol","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis.","author":"Wei","key":"R13-20250504"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/biomedicines10050999","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS)\/drug-induced hypersensitivity syndrome (DiHS)\u2014readdressing the DRESS.","volume":"10","author":"Stirton","year":"2022","journal-title":"Biomedicines"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jaip.2023.02.035","article-title":"Drug reaction with eosinophilia and systemic symptoms: a systematic review.","volume":"11","author":"Awad","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis.","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:47:08Z","timestamp":1746319628000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":16,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039715","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}